708 related articles for article (PubMed ID: 12037148)
1. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
Herold KC; Hagopian W; Auger JA; Poumian-Ruiz E; Taylor L; Donaldson D; Gitelman SE; Harlan DM; Xu D; Zivin RA; Bluestone JA
N Engl J Med; 2002 May; 346(22):1692-8. PubMed ID: 12037148
[TBL] [Abstract][Full Text] [Related]
2. Use of anti-CD3 monoclonal antibody to induce immune regulation in type 1 diabetes.
Bisikirska BC; Herold KC
Ann N Y Acad Sci; 2004 Dec; 1037():1-9. PubMed ID: 15699486
[TBL] [Abstract][Full Text] [Related]
3. A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
Herold KC; Gitelman SE; Masharani U; Hagopian W; Bisikirska B; Donaldson D; Rother K; Diamond B; Harlan DM; Bluestone JA
Diabetes; 2005 Jun; 54(6):1763-9. PubMed ID: 15919798
[TBL] [Abstract][Full Text] [Related]
4. CD3 monoclonal antibodies: a first step towards operational immune tolerance in the clinic.
Chatenoud L; Waldmann H
Rev Diabet Stud; 2012; 9(4):372-81. PubMed ID: 23804274
[TBL] [Abstract][Full Text] [Related]
5. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Sherry N; Hagopian W; Ludvigsson J; Jain SM; Wahlen J; Ferry RJ; Bode B; Aronoff S; Holland C; Carlin D; King KL; Wilder RL; Pillemer S; Bonvini E; Johnson S; Stein KE; Koenig S; Herold KC; Daifotis AG;
Lancet; 2011 Aug; 378(9790):487-97. PubMed ID: 21719095
[TBL] [Abstract][Full Text] [Related]
6. Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7 years from diagnosis.
Perdigoto AL; Preston-Hurlburt P; Clark P; Long SA; Linsley PS; Harris KM; Gitelman SE; Greenbaum CJ; Gottlieb PA; Hagopian W; Woodwyk A; Dziura J; Herold KC;
Diabetologia; 2019 Apr; 62(4):655-664. PubMed ID: 30569273
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Type 1 diabetes with anti-CD3 monoclonal antibody: induction of immune regulation?
Herold KC; Taylor L
Immunol Res; 2003; 28(2):141-50. PubMed ID: 14610290
[TBL] [Abstract][Full Text] [Related]
8. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
Pescovitz MD; Greenbaum CJ; Krause-Steinrauf H; Becker DJ; Gitelman SE; Goland R; Gottlieb PA; Marks JB; McGee PF; Moran AM; Raskin P; Rodriguez H; Schatz DA; Wherrett D; Wilson DM; Lachin JM; Skyler JS;
N Engl J Med; 2009 Nov; 361(22):2143-52. PubMed ID: 19940299
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of anti-CD3 monoclonal antibodies in delaying the progression of recent-onset type 1 diabetes mellitus: A systematic review, meta-analyses and meta-regression.
Ashraf MT; Ahmed Rizvi SH; Kashif MAB; Shakeel Khan MK; Ahmed SH; Asghar MS
Diabetes Obes Metab; 2023 Nov; 25(11):3377-3389. PubMed ID: 37580969
[TBL] [Abstract][Full Text] [Related]
10. Golimumab and Beta-Cell Function in Youth with New-Onset Type 1 Diabetes.
Quattrin T; Haller MJ; Steck AK; Felner EI; Li Y; Xia Y; Leu JH; Zoka R; Hedrick JA; Rigby MR; Vercruysse F;
N Engl J Med; 2020 Nov; 383(21):2007-2017. PubMed ID: 33207093
[TBL] [Abstract][Full Text] [Related]
11. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Keymeulen B; Vandemeulebroucke E; Ziegler AG; Mathieu C; Kaufman L; Hale G; Gorus F; Goldman M; Walter M; Candon S; Schandene L; Crenier L; De Block C; Seigneurin JM; De Pauw P; Pierard D; Weets I; Rebello P; Bird P; Berrie E; Frewin M; Waldmann H; Bach JF; Pipeleers D; Chatenoud L
N Engl J Med; 2005 Jun; 352(25):2598-608. PubMed ID: 15972866
[TBL] [Abstract][Full Text] [Related]
12. An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes.
Herold KC; Bundy BN; Long SA; Bluestone JA; DiMeglio LA; Dufort MJ; Gitelman SE; Gottlieb PA; Krischer JP; Linsley PS; Marks JB; Moore W; Moran A; Rodriguez H; Russell WE; Schatz D; Skyler JS; Tsalikian E; Wherrett DK; Ziegler AG; Greenbaum CJ;
N Engl J Med; 2019 Aug; 381(7):603-613. PubMed ID: 31180194
[TBL] [Abstract][Full Text] [Related]
13. Nonmitogenic CD3 antibody reverses virally induced (rat insulin promoter-lymphocytic choriomeningitis virus) autoimmune diabetes without impeding viral clearance.
von Herrath MG; Coon B; Wolfe T; Chatenoud L
J Immunol; 2002 Jan; 168(2):933-41. PubMed ID: 11777992
[TBL] [Abstract][Full Text] [Related]
14. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Herold KC; Gitelman S; Greenbaum C; Puck J; Hagopian W; Gottlieb P; Sayre P; Bianchine P; Wong E; Seyfert-Margolis V; Bourcier K; Bluestone JA;
Clin Immunol; 2009 Aug; 132(2):166-73. PubMed ID: 19443276
[TBL] [Abstract][Full Text] [Related]
15. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.
Aronson R; Gottlieb PA; Christiansen JS; Donner TW; Bosi E; Bode BW; Pozzilli P;
Diabetes Care; 2014 Oct; 37(10):2746-54. PubMed ID: 25011949
[TBL] [Abstract][Full Text] [Related]
16. Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF.
Ablamunits V; Bisikirska B; Herold KC
Eur J Immunol; 2010 Oct; 40(10):2891-901. PubMed ID: 21038470
[TBL] [Abstract][Full Text] [Related]
17. Activation of human T cells by FcR nonbinding anti-CD3 mAb, hOKT3gamma1(Ala-Ala).
Herold KC; Burton JB; Francois F; Poumian-Ruiz E; Glandt M; Bluestone JA
J Clin Invest; 2003 Feb; 111(3):409-18. PubMed ID: 12569167
[TBL] [Abstract][Full Text] [Related]
18. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody.
Hering BJ; Kandaswamy R; Harmon JV; Ansite JD; Clemmings SM; Sakai T; Paraskevas S; Eckman PM; Sageshima J; Nakano M; Sawada T; Matsumoto I; Zhang HJ; Sutherland DE; Bluestone JA
Am J Transplant; 2004 Mar; 4(3):390-401. PubMed ID: 14961992
[TBL] [Abstract][Full Text] [Related]
19. Remodeling T cell compartments during anti-CD3 immunotherapy of type 1 diabetes.
Long SA; Thorpe J; Herold KC; Ehlers M; Sanda S; Lim N; Linsley PS; Nepom GT; Harris KM
Cell Immunol; 2017 Sep; 319():3-9. PubMed ID: 28844471
[TBL] [Abstract][Full Text] [Related]
20. Partial and transient modulation of the CD3-T-cell receptor complex, elicited by low-dose regimens of monoclonal anti-CD3, is sufficient to induce disease remission in non-obese diabetic mice.
Mehta DS; Christmas RA; Waldmann H; Rosenzweig M
Immunology; 2010 May; 130(1):103-13. PubMed ID: 20059577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
